** U.S.-listed shares of uniQure NV QURE.O up 7.6% to $47.76 on Tues as Dutch drugmaker looks to raise equity on heels of U.S. FDA reversing its earlier position on co's Huntington's disease treatment

** QURE late Mon kicked off $150 mln offering of stock and pre-funded warrants

** Last Weds, co's shares surged ~78% to close at $48.16 after U.S. health regulator said it will accept existing trial data for an accelerated review of AMT-130

** QURE intends to use net proceeds from offering to fund commercialization activities, potential commercial launches and studies of AMT-130, and to develop other product candidates, among other purposes, per the prospectus

** Leerink Partners and Stifel joint bookrunners

** Co has ~63.1 mln shares outstanding

** With the advance, U.S.-listed shares have doubled YTD

** 13 of 15 analysts rate the shares "strong buy" or "buy", 2 "hold"; median PT $60.50, per LSEG